SCHEMBL345532

SCHEMBL345532

COc1cc2c(c(Cl)c1O)Oc1c(cc(OC)c(O)c1Cl)C21OC(=O)c2cc(C(=O)O)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNG2 P59768 1/20 0.40
GNB1 P62873 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
USP2 O75604 2/20 0.39
RECQL P46063 2/20 0.39
BLM P54132 2/20 0.39
ACE2 Q9BYF1 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
PRMT1 Q99873 2/20 0.39
THRB P10828 1/20 0.39
CDK2 P24941 1/20 0.39
CHAT P28329 1/20 0.39
BLVRB P30043 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PKM P14618 2/20 0.39
GAA P10253 1/20 0.39
HTT P42858 3/20 0.38
CA12 O43570 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29831001 1.00 GNG2 (0.40) GNG2GNB1MEN1KMT2AUSP2
SCHEMBL29838713 0.92 MEN1 (0.39) GNG2GNB1MEN1KMT2AUSP2
SCHEMBL29353753 0.92 MEN1 (0.39) GNG2GNB1MEN1KMT2AUSP2
SCHEMBL16118 0.92 MEN1 (0.39) GNG2GNB1MEN1KMT2AUSP2
SCHEMBL7970054 0.88 GNG2 (0.40) GNG2GNB1MEN1KMT2AUSP2
SCHEMBL20353144 0.86 PRMT1 (0.44) GNG2GNB1MEN1KMT2AUSP2
SCHEMBL1738599 0.86 MEN1 (0.33) GNG2GNB1MEN1KMT2AUSP2
SCHEMBL3358989 0.86 MEN1 (0.33) GNG2GNB1MEN1KMT2AUSP2
SCHEMBL203192 0.86 GNG2 (0.43) GNG2GNB1MEN1KMT2AUSP2
Succinimide SCHEMBL25268120 0.86 MEN1 (0.35) GNG2GNB1MEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4524568-A2 METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS Astellas Institute for Regenerative Medicine (US) 2025-03-19 EP claimed
EP-3875599-B1 METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS ASTELLAS INST FOR REGENERATIVE MEDICINE (US) 2024-12-11 EP claimed
US-20220146431-A1 REAGENTS AND METHODS FOR DETECTING INFECTIOUS DISEASES IONICA SCIENCES 2022-05-12 US claimed
US-11300519-B2 Reagents and methods for detecting infectious diseases IONICA SCIENCES (US) 2022-04-12 US claimed
EP-3514176-B1 ANTIBODY SPECIFICALLY BINDING TO IL-17A AND FUNCTIONAL FRAGMENT THEREOF BEIJING HANMI PHARMACEUTICAL CO LTD (CN) 2021-12-15 EP claimed
EP-3875599-A1 METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS Astellas Institute for Regenerative Medicine (US) 2021-09-08 EP claimed
EP-2596119-B1 METHODS FOR DETECTION OF RARE SUBPOPULATIONS OF CELLS AND HIGHLY PURIFIED COMPOSITIONS OF CELLS ASTELLAS INST FOR REGENERATIVE MEDICINE (US) 2021-04-28 EP claimed
US-20190256588-A1 ANTIBODY SPECIFICALLY BINDING TO IL-17A AND FUNCTIONAL FRAGMENT THEREOF BEIJING HANMI PHARM. CO., LTD. (CN) 2019-08-22 US claimed
EP-3514176-A1 ANTIBODY SPECIFICALLY BINDING TO IL-17A AND FUNCTIONAL FRAGMENT THEREOF Beijing Hanmi Pharmaceutical Co., Ltd. (CN) 2019-07-24 EP claimed
EP-2764362-B1 DYE CONJUGATED PEPTIDES FOR FLUORESCENT IMAGING IMMUNOMEDICS INC (US) 2018-09-05 EP claimed
WO-2009020680-A2 MOLECULAR IMAGING OF LIVING SUBJECTS USING RAMAN SPECTROSCOPY AND LABELED RAMAN NANOPARTICLES STANFORD UNIVERSITY (US) 2009-02-12 WO claimed
EP-1937851-A2 METHODS AND COMPOSITIONS FOR GENERATING BIOACTIVE ASSEMBLIES OF INCREASED COMPLEXITY AND USES IBC Pharmaceuticals, Inc. (US) 2008-07-02 EP claimed
EP-1874824-A2 METHODS FOR GENERATING STABLY LINKED COMPLEXES COMPOSED OF HOMODIMERS, HOMOTETRAMERS OR DIMERS OF DIMERS AND USES IBC Pharmaceuticals, Inc. (US) 2008-01-09 EP claimed
US-20070264265-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH CONJUGATED ANTIBODIES OR ANTIBODY FRAGMENTS IMMUNOMEDICS, INC. 2007-11-15 US claimed
WO-2007046893-A2 METHODS FOR GENERATING BIOACTIVE ASSEMBLIES AND USES THEREOF IBC PHARMACEUTICALS, INC. (US) 2007-04-26 WO claimed
US-20070086942-A1 Fusion propteins; homogeneous purity, and unaltered affinity, and can be produced in high yields without the requirement of extensive purification; stable in serum to allow in vivo applications IBC PHARMACEUTICALS, INC. 2007-04-19 US claimed
WO-2006107617-A2 METHODS FOR GENERATING STABLY LINKED COMPLEXES COMPOSED OF HOMODIMERS, HOMOTETRAMERS OR DIMERS OF DIMERS AND USES IBC PHARMACEUTICALS, INC. (US) 2006-10-12 WO claimed
US-20060228357-A1 dimerization and docking domains; fusion proteins IBC PHARMACEUTICALS, INC. 2006-10-12 US claimed
US-7057025-B2 Binary probe and clamp composition APPLERA CORPORATION (US) 2006-06-06 US claimed
US-20060035217-A1 BINARY PROBE AND CLAMP COMPOSITION. PE CORPORATION (NY) (US) 2006-02-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035217-A1 BINARY PROBE AND CLAMP COMPOSITION. RNGTT, FEN1, POLL GNG2 720/4885GNB1 816/4885MEN1 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.